ALKS Alkermes plc

Price (delayed)

$25.56

Market cap

$4.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.58

Enterprise value

$4.24B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
Alkermes's gross profit has decreased by 4.7% YoY but it has increased by 2.5% from the previous quarter
The revenue has contracted by 3.6% YoY but it has grown by 2.6% from the previous quarter
Alkermes's net income has decreased by 46% from the previous quarter and by 25% YoY
The EPS has declined by 45% since the previous quarter and by 26% year-on-year

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
161.71M
Market cap
$4.13B
Enterprise value
$4.24B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.76
Price to sales (P/S)
3.65
EV/EBIT
N/A
EV/EBITDA
577.77
EV/Sales
3.76
Earnings
Revenue
$1.13B
EBIT
-$70.5M
EBITDA
$7.34M
Free cash flow
$114.1M
Per share
EPS
-$0.58
Free cash flow per share
$0.71
Book value per share
$6.79
Revenue per share
$6.99
TBVPS
$11.27
Balance sheet
Total assets
$2B
Total liabilities
$899.26M
Debt
$419.85M
Equity
$1.1B
Working capital
$600.02M
Liquidity
Debt to equity
0.38
Current ratio
2.32
Quick ratio
1.88
Net debt/EBITDA
14.9
Margins
EBITDA margin
0.7%
Gross margin
83.5%
Net margin
-8.1%
Operating margin
-5.5%
Efficiency
Return on assets
-4.7%
Return on equity
-8.5%
Return on invested capital
-4.7%
Return on capital employed
-4.6%
Return on sales
-6.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
6.5%
1 week
1.23%
1 month
6.1%
1 year
15.19%
YTD
9.89%
QTD
9.89%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.13B
Gross profit
$942.66M
Operating income
-$62.4M
Net income
-$91.68M
Gross margin
83.5%
Net margin
-8.1%
Alkermes's net income has decreased by 46% from the previous quarter and by 25% YoY
The net margin has contracted by 42% from the previous quarter and by 29% YoY
Alkermes's operating income has increased by 32% YoY but it has decreased by 17% from the previous quarter
The company's operating margin rose by 29% YoY but it fell by 12% QoQ

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
P/E
N/A
P/B
3.76
P/S
3.65
EV/EBIT
N/A
EV/EBITDA
577.77
EV/Sales
3.76
The EPS has declined by 45% since the previous quarter and by 26% year-on-year
The P/B is 23% lower than the 5-year quarterly average of 4.6
ALKS's P/S is 36% below its 5-year quarterly average of 5.4 and 2% below its last 4 quarters average of 3.5
The revenue has contracted by 3.6% YoY but it has grown by 2.6% from the previous quarter

Efficiency

How efficient is Alkermes business performance
The ROIC has plunged by 62% from the previous quarter and by 38% YoY
The ROS has dropped by 59% since the previous quarter and by 51% year-on-year
The return on equity has declined by 47% since the previous quarter and by 23% year-on-year
The ROA fell by 42% QoQ and by 18% YoY

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 122% higher than its total liabilities
ALKS's quick ratio is down by 15% year-on-year and by 14% since the previous quarter
The current ratio has contracted by 14% from the previous quarter and by 14% YoY
The debt is 62% less than the equity
The debt has grown by 9% YoY
The debt to equity is up by 6% YoY but it is down by 2.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.